Standout Papers

Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer 2002 2026 2010 2018 4.0k
  1. Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer (2002)
    Joan H. Schiller, David Harrington et al. New England Journal of Medicine
  2. Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (2004)
    David H. Johnson, Louis Fehrenbacher et al. Journal of Clinical Oncology
  3. Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1 (2004)
    Giuseppe Giaccone, Roy S. Herbst et al. Journal of Clinical Oncology
  4. Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2 (2004)
    Roy S. Herbst, Giuseppe Giaccone et al. Journal of Clinical Oncology
  5. Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib (2005)
    David A. Eberhard, Bruce E. Johnson et al. Journal of Clinical Oncology
  6. TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer (2005)
    Roy S. Herbst, Diane Prager et al. Journal of Clinical Oncology
  7. American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003 (2003)
    David G. Pfister, David H. Johnson et al. Journal of Clinical Oncology
  8. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial (2009)
    Kathy S. Albain, Ruth Swann et al. The Lancet
  9. American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer (2009)
    Christopher G. Azzoli, Sherman Baker et al. Journal of Clinical Oncology
  10. Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials (2005)
    Daphne W. Bell, Thomas J. Lynch et al. Journal of Clinical Oncology
  11. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data (2010)
    R. Arriagada, A. Aupérin et al. The Lancet
  12. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy (2011)
    Vicki L. Keedy, Sarah Temin et al. Journal of Clinical Oncology

Immediate Impact

3 by Nobel laureates 20 from Science/Nature 182 standout
Sub-graph 1 of 13

Citing Papers

Outcomes after Critical Illness
2023 Standout
Lung cancer
2021 Standout
53 intermediate papers

Works of David H. Johnson being referenced

Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data
2010 Standout
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
2002 Standout
and 29 more

Author Peers

Author Last Decade Papers Cites
David H. Johnson 18124 14852 2203 5643 241 25.8k
Corey J. Langer 16729 17063 3108 5718 556 27.9k
Keunchil Park 16632 17565 2605 6064 564 26.7k
Julie R. Brahmer 18304 28602 2281 7584 349 37.4k
Yutaka Nishiwaki 14437 13174 1391 4773 272 20.8k
John Crowley 9380 12418 1857 10172 335 27.3k
Giorgio V. Scagliotti 19104 16694 2670 8252 475 28.9k
D. Ross Camidge 16480 14715 1395 8384 533 23.6k
Eric K. Rowinsky 9456 18262 3712 11946 392 31.5k
David R. Gandara 18069 16654 2455 7907 641 29.1k
Lesley Seymour 13259 13446 1763 5180 256 21.7k

All Works

Loading papers...

Rankless by CCL
2026